$RPTX
Repare Therapeutics Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023019671 Filed on May 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $30.25M $5.678M $408.0K
YoY Change 4354.93% 1291.67% 140.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.719M $8.529M $8.779M
YoY Change 9.84% -2.85% 67.54%
% of Gross Profit
Research & Development $33.79M $31.83M $26.46M
YoY Change 7.35% 20.3% 60.26%
% of Gross Profit
Depreciation & Amortization $506.0K $441.0K $516.0K
YoY Change -3.25% -14.53% 60.25%
% of Gross Profit
Operating Expenses $42.51M $40.36M $35.24M
YoY Change 7.85% 14.54% 62.04%
Operating Profit -$12.26M -$34.68M -$34.83M
YoY Change -68.35% -0.42% 61.39%
Interest Expense $3.448M $3.371M $112.0K
YoY Change 403.36% 2909.82% 273.33%
% of Operating Profit
Other Income/Expense, Net $3.422M $3.356M $104.0K
YoY Change 407.72% 3126.92% 300.0%
Pretax Income -$8.836M -$31.33M -$34.73M
YoY Change -76.78% -9.79% 61.11%
Income Tax $3.110M $3.616M $32.00K
% Of Pretax Income
Net Earnings -$11.95M -$34.94M -$34.76M
YoY Change -68.64% 0.53% 62.29%
Net Earnings / Revenue -39.49% -615.38% -8518.87%
Basic Earnings Per Share -$0.28 -$0.83 -$0.83
Diluted Earnings Per Share -$0.28 -$0.83 -$830.3K
COMMON SHARES
Basic Shares Outstanding 42.09M 42.08M 41.87M
Diluted Shares Outstanding 42.09M 42.04M 41.86M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $280.7M $314.1M $305.1M
YoY Change 1.76% 2.95% -2.01%
Cash & Equivalents $115.5M $121.5M $305.1M
Short-Term Investments $165.1M $192.7M $6.528M
Other Short-Term Assets $4.201M $4.389M $3.915M
YoY Change 29.58% 12.11% 0.38%
Inventory
Prepaid Expenses $4.201M $4.389M $3.915M
Receivables
Other Receivables $5.281M
Total Short-Term Assets $291.9M $325.5M $319.2M
YoY Change 0.75% 1.97% -2.73%
LONG-TERM ASSETS
Property, Plant & Equipment $4.821M $5.396M $5.397M
YoY Change -5.91% -0.02% -38.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $408.0K $408.0K $586.0K
YoY Change -17.91% -30.38% -72.1%
Total Long-Term Assets $9.663M $10.78M $17.92M
YoY Change -47.21% -39.85% 64.41%
TOTAL ASSETS
Total Short-Term Assets $291.9M $325.5M $319.2M
Total Long-Term Assets $9.663M $10.78M $17.92M
Total Assets $301.6M $336.3M $337.1M
YoY Change -2.1% -0.25% -0.58%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.893M $3.620M $1.546M
YoY Change -1.96% 134.15% -54.53%
Accrued Expenses $23.70M $19.54M $18.47M
YoY Change 7.71% 5.82% 184.08%
Deferred Revenue $24.41M $52.76M $11.87M
YoY Change 105.92% 344.33%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $53.25M $80.94M $34.08M
YoY Change 35.02% 137.46% 174.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.921M $4.127M $44.41M
YoY Change -93.22% -90.71% -24.74%
Total Long-Term Liabilities $2.921M $4.127M $44.41M
YoY Change -93.22% -90.71% -24.74%
TOTAL LIABILITIES
Total Short-Term Liabilities $53.25M $80.94M $34.08M
Total Long-Term Liabilities $2.921M $4.127M $44.41M
Total Liabilities $56.17M $85.06M $78.49M
YoY Change -31.93% 8.37% 9.93%
SHAREHOLDERS EQUITY
Retained Earnings -$286.2M -$274.3M -$245.0M
YoY Change 1.09% 11.93%
Common Stock $532.0M $525.7M $503.7M
YoY Change 4.6% 4.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $245.4M $251.2M $258.7M
YoY Change
Total Liabilities & Shareholders Equity $301.6M $336.3M $337.1M
YoY Change -2.1% -0.25% -0.58%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$11.95M -$34.94M -$34.76M
YoY Change -68.64% 0.53% 62.29%
Depreciation, Depletion And Amortization $506.0K $441.0K $516.0K
YoY Change -3.25% -14.53% 60.25%
Cash From Operating Activities -$34.35M -$31.79M -$30.01M
YoY Change 21.82% 5.93% 110.91%
INVESTING ACTIVITIES
Capital Expenditures $1.065M $475.0K $487.0K
YoY Change -167.88% -2.46% -36.92%
Acquisitions
YoY Change
Other Investing Activities $29.42M -$6.211M $890.0K
YoY Change 11213.46% -797.87%
Cash From Investing Activities $28.35M -$6.686M $403.0K
YoY Change -2265.78% -1759.06% -152.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 40.00K 413.0K 241.0K
YoY Change -80.49% 71.37% 31.69%
NET CHANGE
Cash From Operating Activities -34.35M -31.79M -30.01M
Cash From Investing Activities 28.35M -6.686M 403.0K
Cash From Financing Activities 40.00K 413.0K 241.0K
Net Change In Cash -5.956M -38.06M -29.29M
YoY Change -79.67% 29.94% 98.15%
FREE CASH FLOW
Cash From Operating Activities -$34.35M -$31.79M -$30.01M
Capital Expenditures $1.065M $475.0K $487.0K
Free Cash Flow -$35.41M -$32.26M -$30.49M
YoY Change 33.0% 5.8% 103.3%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2023Q1 rptx Additional Paid In Capital Share Based Payment Arrangement Exercised Options Credited To Common Shares
AdditionalPaidInCapitalShareBasedPaymentArrangementExercisedOptionsCreditedToCommonShares
0
CY2023Q1 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2023Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39335
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7210 Frederick-Banting
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 100
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2023Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 2A1
CY2023Q1 dei City Area Code
CityAreaCode
857
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
412-7018
CY2023Q1 dei Security12b Title
Security12bTitle
Common shares, no par value
CY2023Q1 dei Trading Symbol
TradingSymbol
RPTX
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42088446
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
121461000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
159521000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
192663000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
184420000
CY2023Q1 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1659000
CY2022Q4 rptx Research And Development Tax Credits Receivable
ResearchAndDevelopmentTaxCreditsReceivable
1280000
CY2023Q1 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
3996000
CY2022Q4 us-gaap Receivables Long Term Contracts Or Programs
ReceivablesLongTermContractsOrPrograms
1525000
CY2023Q1 us-gaap Other Receivables
OtherReceivables
1358000
CY2022Q4 us-gaap Other Receivables
OtherReceivables
1518000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4389000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5715000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
325526000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
353979000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
5396000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4228000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4976000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5371000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
408000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
497000
CY2023Q1 us-gaap Assets
Assets
336306000
CY2022Q4 us-gaap Assets
Assets
364075000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
3620000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
17442000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
21645000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2257000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2171000
CY2023Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
52760000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
53102000
CY2023Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
4856000
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1240000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
80935000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
78619000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2780000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3257000
CY2023Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1347000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2682000
CY2023Q1 us-gaap Liabilities
Liabilities
85062000
CY2023Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2022Q4 us-gaap Liabilities
Liabilities
84558000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34941000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2022Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42079896
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42079896
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42036193
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42036193
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
482677000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
482032000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
43056000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
37226000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-235000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-428000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-274254000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-239313000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
251244000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
336306000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364075000
CY2023Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
5678000
CY2022Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
408000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31830000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
26458000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8529000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8779000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
40359000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
35237000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34681000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34829000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-56000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-17000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
3427000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
129000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000
CY2022Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
8000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3356000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31325000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-34725000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3616000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
32000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34757000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
193000
CY2022Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
0
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34748000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34757000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42040674
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42040674
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41861613
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41861613
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
288421000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
28000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4755000
CY2022Q1 rptx Net Income Loss And Comprehensive Income Loss
NetIncomeLossAndComprehensiveIncomeLoss
-34757000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
258660000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
193000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34941000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
251244000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34941000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-34757000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6062000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4755000
CY2023Q1 us-gaap Depreciation
Depreciation
441000
CY2022Q1 us-gaap Depreciation
Depreciation
516000
CY2023Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
541000
CY2022Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
544000
CY2023Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-66000
CY2022Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
40000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1839000
CY2022Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-21000
CY2023Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
0
CY2022Q1 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
1315000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1330000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-2399000
CY2023Q1 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
379000
CY2022Q1 rptx Increase Decrease In Research And Development Tax Credits Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditsReceivable
399000
CY2023Q1 rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
2528000
CY2022Q1 rptx Increase Decrease In Collaboration Revenue Receivable
IncreaseDecreaseInCollaborationRevenueReceivable
0
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-166000
CY2022Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
5000
CY2023Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
200000
CY2022Q1 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
CY2022Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2016000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-772000
CY2023Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-4203000
CY2022Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-1487000
CY2023Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
35000
CY2022Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
153000
CY2023Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
3616000
CY2022Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
1347000
CY2023Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-581000
CY2022Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-558000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1677000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-408000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31786000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30006000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
475000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
487000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
92500000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2650000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
98711000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
1760000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6686000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
403000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
28000
CY2023Q1 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
409000
CY2022Q1 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
213000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
413000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
241000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
71000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38060000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-29291000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
334427000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121461000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
305136000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1134000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1541000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
146000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
118200000
CY2022Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
157900000
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2022Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023Q1 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2016-09-06
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">assumptions </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation, right-of-use assets and lease liabilities and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2023Q1 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
200000
CY2022Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2023Q1 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2149000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5616000
CY2023Q1 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
14410000
CY2022Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
15078000
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
724000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
680000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
159000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
271000
CY2023Q1 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
17442000
CY2022Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
21645000
CY2023Q1 rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2023Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
592000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
615000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.24
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
8000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
40000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
67000
CY2023Q1 us-gaap Lease Cost
LeaseCost
646000
CY2022Q1 us-gaap Lease Cost
LeaseCost
690000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
599000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
475000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
146000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
56000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M8D
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y1M28D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.040
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8032902
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.38
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1569640
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.30
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.24
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
27713
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
18.92
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9572829
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.03
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.17
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0365
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0173
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y29D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8177
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7847
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4755000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4755000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34941000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34757000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42040674
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42040674
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41861613
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41861613
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83

Files In Submission

Name View Source Status
rptx-20230331_cal.xml Edgar Link unprocessable
0000950170-23-019671-index-headers.html Edgar Link pending
0000950170-23-019671-index.html Edgar Link pending
0000950170-23-019671.txt Edgar Link pending
0000950170-23-019671-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20230331.htm Edgar Link pending
rptx-20230331.xsd Edgar Link pending
rptx-ex10_1.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
rptx-ex32_2.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20230331_def.xml Edgar Link unprocessable
rptx-20230331_lab.xml Edgar Link unprocessable
rptx-20230331_pre.xml Edgar Link unprocessable
rptx-20230331_htm.xml Edgar Link completed